The investigational drug Abiraterone, designed for the treatment of men with advanced prostate cancer who have failed chemotherapy has not yet been approved by the FDA. Because of the extraordinarily positive results that were obtained on the phase III trials (which were stopped early because of these fantastic results) the pharmaceutical manufacturer of the drug [...]
Applications for the approval of Abiraterone Acetate (Abiraterone) have been submitted to both the U.S. Food and Drug Administration (FDA) and to the European Medicines Agency (EMA). The applications are for the approval of Abiraterone with prednisone for the treatment of metastatic advanced prostate cancer in men who have received prior chemotherapy containing a taxane. [...]
GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial treating men with advanced prostate cancer, at the Annual Meeting of the Society of Urologic Oncology. Capesaris is a novel oral selective estrogen receptor alpha agonist which GTx is developing for first line treatment of advanced prostate cancer. [...]
Bavarian Nordic A/S today announced that they have received a letter of concurrence from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 study required for product registration for its product candidate, PROSTVAC®, for the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer [...]
Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]